Insuline et prise de poids

Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a Franch, 2005, Molecular signaling pathways regulating muscle proteolysis during atrophy Curr. Opin. Clin. Nutr. Metab, Care, 8, 271 Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005 1995, – U K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U. K. Prospective Diabetes Study Group, Diabetes, 44, 1249, 10.2337/diab.44.11.1249 1993, – The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med, 329, 977, 10.1056/NEJM199309303291401 Yki-Jarvinen, 1992, Glucose toxicity, Endocr. Rev, 13, 415 Prise en charge du diabète, diabète de type 2, HAS/Afssaps novembre 2006 (téléchargeable sur http://www.has-sante.fr). 1997, – Hypoglycemia in the Diabetes Control and Complications Trial The Diabetes Control and Complications Trial Research Group, Diabetes, 46, 271, 10.2337/diab.46.2.271 2001, – Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial, Diabetes Care, 24, 1711, 10.2337/diacare.24.10.1711 Purnell, 2003, Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial, Diabetes, 52, 2623, 10.2337/diabetes.52.10.2623 1998, – Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 Groop, 1989, Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia, 32, 599, 10.1007/BF00285334 Nathan, 1988, Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study, Ann. Intern. Med, 108, 334, 10.7326/0003-4819-108-3-334 Chow, 1995, Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients, Diabetes Care, 18, 307, 10.2337/diacare.18.3.307 Lindstrom, 1994, Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure, Diabetes Care, 17, 719, 10.2337/diacare.17.7.719 Yki-Jarvinen, 1997, Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab, 82, 4037, 10.1210/jcem.82.12.4460 Sinha, 1996, Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes, Diabet. Med, 13, 40, 10.1002/(SICI)1096-9136(199601)13:1<40::AID-DIA991>3.0.CO;2-U Larger, 2004, Insulin therapy does not itself induce weight gain in patients with type 2 diabetes, Diabetes Care, 10, 1849 Larger, 2005, Weight gain and insulin treatment, Diabetes Metab., 31, 4S51 Rigalleau, 1999, Composition of insulin-induced body weight gain in diabetic patients: a bio-impedance study, Diabetes Metab, 25, 321 Makimattila, 1999, Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus, Diabetologia, 42, 406, 10.1007/s001250051172 Nathan, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N. Engl. J. Med., 353, 2643, 10.1056/NEJMoa052187 Lindstrom, 1994, Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure, Diabetes Care, 17, 719, 10.2337/diacare.17.7.719 Cosson, 2005, Modalités d’utilisation des analogues rapides et mixtes de l’insuline par les diabétologues L’étude ARAMIS, Diabetes Metab, 31, S99 Fritsche, 2004, At last, a weight neutral insulin? Int, J. Obes. Relat. Metab. Disord, 28, 41, 10.1038/sj.ijo.0802749 Hordern, 2005, Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp, Diabetologia, 48, 420, 10.1007/s00125-005-1670-1 Hordern, 2005, Insulin detemir, does a new century bring a better basal insulin?, Int J. Clin. Pract, 59, 730, 10.1111/j.1368-5031.2005.00544.x Vague, 2003, Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart, Diabetes Care, 26, 590, 10.2337/diacare.26.3.590 Hermansen, 2004, Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes, Diabetologia, 47, 622, 10.1007/s00125-004-1365-z Haak, 2005, Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes, Diabetes Obes. Metab, 7, 56, 10.1111/j.1463-1326.2004.00373.x Standl, 2004, The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes, Diabetes Technol. Ther, 6, 579, 10.1089/dia.2004.6.579 Raslova, 2004, Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes, Diabetes Res. Clin. Pract, 66, 193, 10.1016/j.diabres.2004.03.003